Company intelligence / Profile preview
Dioseve
Tokyo, Tokyo, Japandioseve.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Dioseve is developing assisted reproductive technology using oocytes derived from iPS cells. Their proprietary differentiation induction technology efficiently induces oocytes and ovarian somatic cells from iPS cells. The technology allows for producing oocytes in a short period without expensive growth factors or advanced techniques required by existing methods, enabling cheap and large-scale oocyte production[2].
- Therapeutic areas
- Women's Health
- Modalities
- Cell therapyiPS cell-derived oocytes
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Dioseve.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dioseve.